Over 350 Total Lots Up For Auction at Two Locations - NY 03/21, FL 03/22

New PET radiotracer for prostate cancer found to be safe and effective

by Lauren Dubinsky, Senior Reporter | February 03, 2017
Molecular Imaging Rad Oncology
Ga-68-BBN PET/CT of a
64-year-old man newly diagnosed
with prostate cancer by biopsy

Courtesy of
Peking Union Medical College
In the latest issue of the Journal of Nuclear Medicine, researchers have confirmed that a new PET radio tracer for diagnosing primary and metastatic prostate cancer is safe and effective.

The gallium-68-labeled peptide BBN-RGD agent targets both gastrin-releasing peptide receptor and integrin αvβ3. Unlike single-receptor targeting, dual-receptor targeting allows for tumor contrast when either or both receptor types are expressed.

"This approach is better than targeting a single receptor," Dr. Xiaoyuan Chen, senior investigator of the study, told HCB News. "In other words, the sensitivity of detection is improved [over] other radiotracers."
stats
DOTmed text ad

Your Centrifuge Specialty Store

Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576

stats
The study involved 13 patients with prostate cancer. Four were newly diagnosed, nine received therapy, and five were healthy volunteers.

They found that Ga-68-BBN-RGD PET/CT was able to detect 20 bone lesions in seven patients with primary prostate cancer or after radical prostatectomy. The patients with bone metastases didn't necessarily have elevated prostate specific antigen level.

Since no adverse events were reported during the procedure and at the two-week follow-up, Ga-68-BBN-RGD was deemed safe.

Chen noted that this is a better result than bone scanning with the most common radio tracer used today, technetium-99m-MDP. MDP bone scans are sensitive, but lack specificity because localized skeletal accumulation of Tc-99m-MDP can also be observed in trauma and infection cases.

"It may become the standard for diagnosing prostate cancer," said Chen. "Another major application of this would be using the same peptide construct to label therapeutic isotopes or cytotoxic agents for targeted treatment of prostate cancer."

You Must Be Logged In To Post A Comment